| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-06 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.14 | 6e-05 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0003 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.26 | 0.0006 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0008 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |